FDA Transfers BIVIGAM and Nabi-HB Licenses to ADMA Biologics
On July 8, ADMA Biologics, Inc. (ADMA) reported that they now hold the licenses for BIVIGAM and Nabi-HB that previously belonged to Biotest Pharamceuticals. This was the final regulatory item outstanding from ADMA’s acquisition of the Biotest Therapy Business Unit in June 2017. The FDA had to revoke the license from Biotest Pharmaceuticals and perform due diligence on ADMA Biologics before issuing the final transfer of these licenses.
Sonal detected the event at 8:22 am, and regular market trading opened for the day at $3.59. ADMA’s stock price quickly moved higher throughout the event day, and it continued to rise over the next four trading sessions. ADMA closed at $4.07 on July 12 for a 5-day gain of 13.4%.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!